It was in January 2021 the free vaccination against COVID-19 commenced in India and the government urged all of its citizens to get vaccinated which was expected to be the largest vaccination program in the world. Out of the various COVID-19 vaccines that were under various stages of clinical trials in India, four were developed in the country. Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-manufactured vaccine produced by Bharat Biotech had received approval from the Drug Controller of India. Indian manufacturers had stated that they can meet the country\'s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic was sufficient for the initial vaccination of 30 million healthcare workers and was strengthened further to cater to the entire population subsequently. The Indian government had taken urgent measures to expand the country\'s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. It brings in the sequential events in the battle against COVID-19 in India.
Gupta R, Kumar VM, Tripathi M, et al. Guidelines of the Indian Society for Sleep Research (ISSR) for practice of sleep medicine during COVID-19. Sleep Vigil 2020;4(2):1–12. DOI: 10.1007/s41782-020-00097-2.
Pandi-Perumal SR, Gulia KK, Gupta D, et al. Dealing with a pandemic: the Kerala model of containment strategy for COVID-19. Pathog Glob Health 2020;114(5):232–233. DOI: 10.1080/20477724.2020.1778392.
Gulia KK, Kumar VM. Reverse quarantine in Kerala: managing the 2019 novel coronavirus in a state with a relatively large elderly population. Psychogeriatrics 2020;20(5):794–795. DOI: 10.1111/psyg.12582.
Gulia KK, Kumar VM. Importance of sleep for health and wellbeing amidst COVID-19 pandemic. Sleep Vigil May 2020;4(1):1–2. DOI: 10.1007/s41782-020-00087-4.
Cardinali DP, Brown GM, Reiter RJ, et al. Elderly as a high-risk group during COVID-19 pandemic: effect of circadian misalignment, sleep dysregulation and melatonin administration. Sleep Vigil 2020;26(2):1–7. DOI: 10.1007/s41782-020-00111-7.
Gupta I, Baru R. Economics & ethics of the COVID-19 vaccine: how prepared are we? Indian J Med Res 2020;152(1&2):153–155. DOI: 10.4103/ijmr.IJMR_3581_20.
Vignesh R, Shankar EM, Vijayakumar V, et al. Is herd immunity against SAR-CoV2 a silver lining? Front Immunol 2020;11:586781. DOI: 10.3389/fimmu.2020.586781.
Le TT, Cramer JP, Chen R, et al. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020;19(10):667–668. DOI: 10.1038/d41573-020-00151-8.
Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine 2020;38(40):6194–6198. DOI: 10.1016/j.vaccine.2020.07.013.
Krause P, Fleming TR, Longini I, et al. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet 2020;396(10253):741–743. DOI: 10.1016/S0140-6736(20)31821-3.
Zhang Y, Zeng G, Wang H, et al. Safety tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2020;21(1):39–51. DOI: 10.1016/S1473-3099(20)30843-4.
Bar-Zeev N, Kochhar S. Expecting the unexpected with COVID-19 vaccines. Lancet Infect Dis 2020;21(2):150–151. DOI: 10.1016/S1473-3099(20)30870-7.
Vaccine information, ICMR New Delhi—COVID-19 vaccine. https://vaccine.icmr. org.in/covid-19-vaccine (2021).
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99–111. DOI: 10.1016/S0140-6736(20)32661-1.
Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;383(24):2320–2332. DOI: 10.1056/NEJMoa2026920.
Ella R. A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine BBV152, a double-blind, randomised, Phase 1 trial. Lancet Infect Dis 2021;21(7):950–961. DOI: 10.1016/S1473-3099(20)30942-7(2021).
Liu Y, Wang K, Massoud TF, et al. SARS-CoV-2 vaccine development: an overview and perspectives. ACS Pharm Transl Sci 2020;3(5):844–858. DOI: 10.1021/acsptsci.0c00109.
Momin T, Kansagra K, Patel H, et al. Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. E Clin Med 2021;38:101020. DOI: 10.1016/j.eclinm.2021.101020.
Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396(10255):887–897. DOI: 10.1016/S0140-6736(20)31866-3.
Ministry of Health and Family Welfare (2020) COVID-19 Vaccine Operational Guidelines. Ministry of Health and Family Welfare, Government of India. 28 December 2020. https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter16.pdf. (Accessed on 04 June 2021).
Bhuyan A. India begins COVID-19 vaccination amid trial allegations. Lancet 2021;397(10271):P264. DOI: 10.1016/S0140-6736(21) 00145-8.
Sapkal GN, Yadav PD, Ella R, et al., Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. Preprint at https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2 2021.
Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines 2020;8(3):474. DOI: 10.3390/vaccines8030474.
Wolemonwu VC. Human challenge trials for a COVID-19 vaccine: should we bother about exploitation? Voices Bioeth 2020;6:1–6.